Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Letrozole wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Anastrozole and Letrozole have evidence — compare verdict strength side-by-side.
Approved breast-cancer dose is 1 mg once daily. Off-label use in men mirrors this (typically 0.5–1 mg/day or 1 mg 2–3×/week to avoid over-suppressing estradiol) under a clinician, with estradiol and bone monitoring. A prescription drug; not an approved men's-health regimen.
any
Oral tablet (anastrozole)
Indication-specific and clinician-directed. Ovulation induction: 2.5-7.5 mg once daily for 5 days early in the cycle (typically days 3-7). Breast cancer: 2.5 mg once daily continuously. Off-label male use mirrors 2.5 mg once to a few times weekly (NOT daily) titrated to testosterone/estradiol — a prescription drug, not an approved supplement regimen.
any
Oral letrozole 2.5 mg tablet (Femara / generic)
Weeks (peaks ~3 months)
Years
Up to 1 year
Months to years
Per cycle (days 3-7 dosing)
Weeks to months
Months to years
Months to years
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
The Lancet. Oncology (2010) · Rct · n=6241
ATAC 10-year analysis — the pivotal registration RCT in postmenopausal early breast cancer (n=6241; the approved indication)
Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.
Clinical endocrinology (2009) · Rct · n=88
1-year double-blind, placebo-controlled RCT in older hypogonadal men (n=88)
Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.
The Journal of clinical endocrinology and metabolism (2009) · Rct · n=69
1-year double-blind, placebo-controlled RCT in older men with low testosterone (n=69)
Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
The New England journal of medicine (2014) · Rct · n=750
Double-blind multicenter RCT of 750 women with PCOS randomized to letrozole or clomiphene for up to five cycles, primary outcome live birth
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Cochrane Database of Systematic Reviews (2022) · Meta analysis
Cochrane systematic review of 41 RCTs (6522 women); letrozole was used in all trials
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
Cochrane Database of Systematic Reviews (2018) · Meta analysis
Earlier Cochrane systematic review including 42 RCTs (7935 women); letrozole was used in all studies
Letrozole has a higher evidence score (5/10 vs 4.6/10) and wins in 1 of 3 categories.
No known interactions between Anastrozole and Letrozole have been documented in our database. However, always consult a healthcare provider before combining supplements.